Jump to content

Catharine Whiteside

Add links
From Wikipedia, the free encyclopedia
Catharine Whiteside
Alma materUniversity of Toronto
Organization(s)Diabetes Action Canada
University of Toronto
Known for
  • Diabetes Research
  • Medical Leadership
AwardsMember of the Order of Canada
Kidney Foundation of Canada Medal for Research Excellence
Dean of the Faculty of Medicine of the University of Toronto
In office
2006–2014
Preceded byDavid Naylor
Succeeded byTrevor Young
Scientific career
FieldsNephrology
Thesis Glomerular and Postglomerular Capillary Permselectivity in The Dog Kidney  (1984)

Catharine Isobel Whiteside is a Canadian physician and medical researcher. She is Director, Strategic Partnerships of Diabetes Action Canada and Chair of the board of the Banting Research Foundation.[1] Whiteside is the former Dean of the Faculty of Medicine at the University of Toronto.[1]

Education

[edit]

Medical career

[edit]

Whiteside obtained her MD from the University of Toronto (U of T) with certifications in internal medicine and nephrology.[3] Whiteside provides leadership in continuing health education, focused on inter-professional teamwork and patient-centred practice.[4][5]

Whiteside was appointed Director of the Cinician Scientist Training Program at U of T in 1997.[6] Whiteside was graduate coordinator for the Institute of Medical Sciences (IMS) at U of T. In 2003, IMS established the annual Whiteside award in her honour to be presented to a recently graduated MSc student who had made outstanding scholarly contributions.[7]

Whiteside was Dean of Medicine at the University of Toronto from 2006-2014.[3] She is a founding member and former president of the Canadian Academy of Health Sciences.[8]

Whiteside was Executive Director of Diabetes Action Canada from 2016-2021. As Director of the CIHR Strategic Patient-Oriented Research Network for Diabetes and Related Complications, she stated that "Our mission is to improve patient experience, population outcomes and health professional experience, and to reduce health care costs related to diabetes".[9] In 2022 she became Director, Strategic Partnerships for Diabetes Action Canada.[1] Whiteside joined the Board of Directors of Scarborough Health Network in 2022.[10]

Research

[edit]

Whiteside conducted doctoral research on kidney physiology.[11] Her subsequent research examined the effect of diabetes and glucose levels on the interactions of glomerular cells during injury and healing.[5] The glomerular filtration barrier forms the primary filter in the kidneys, but damage to the epithelial glomerular tissue and the endothelial podocytes are common in diabetic nephropathy. This damage affects the kidneys' ability to remove waste products and extract fluid from the body.[12]

Whiteside’s research suggests that early damage to the kidney from high glucose occurs through increased levels of reactive oxygen species (ROS).[13] ROS generation may be a consequence of activation of the polyol pathway and is amplified by protein kinase C (PKC) signalling.[14] PKC activation increases the level of growth factors that contribute to the pathogenesis of diabetic nephropathy, including disassembly of F-actin stress fibres in glomerular mesangial cells.[15][16]

Whiteside studies potential therapeutic mechanisms to reduce the effect of diabetic nephropathies.[17]

Whiteside also studies the management of health sciences in academia.[18][19]

Awards and distinctions

[edit]

References

[edit]
  1. ^ a b c "Administrative Team Archives". Diabetes Action Canada - SPOR Network. Retrieved 2022-08-17.
  2. ^ a b c "A public health visionary: Vivek Goel's remarkable impact during his time at U of T". University of Toronto Alumni. Retrieved Oct 4, 2021.
  3. ^ a b "Catharine Whiteside". University of Calgary. Retrieved 2021-09-03.
  4. ^ The SCRIPT Project Team (2007). "Structuring communication relationships for interprofessional teamwork (SCRIPT): A Canadian initiative aimed at improving patient-centred care". Journal of Interprofessional Care. 21 (1): 111–114. doi:10.1080/13561820600991595. PMID 17365378. S2CID 37568072.
  5. ^ a b c "Dr. Catharine Whiteside". kidney.ca. Retrieved Oct 4, 2021.
  6. ^ Shorter, Edward (2013). Partnership for excellence : medicine at the University of Toronto and academic hospitals. Toronto [Ontario]. p. 204. ISBN 978-1-4426-6403-6. OCLC 863054377.{{cite book}}: CS1 maint: location missing publisher (link)
  7. ^ "Scientific Day Student Awards". ims.utoronto.ca. Retrieved 2022-08-19.
  8. ^ "Past Presidents and Board Members – Canadian Academy of Health Sciences | Académie canadienne des sciences de la santé". Retrieved Oct 4, 2021.
  9. ^ admin (2019-11-07). "Patient-Oriented Research in the Spotlight for Diabetes Awareness Month". Diabetes Action Canada - SPOR Network. Retrieved 2022-08-18.
  10. ^ "SHN Welcomes 2022-2023 Board of Directors – Scarborough Health Network". Retrieved 2022-08-18.
  11. ^ Whiteside, Catharine (1983). "Determination of glomerular permselectivity to neutral dextrans in the dog". American Journal of Physiology. 245 (4): F485–F495. doi:10.1152/ajprenal.1983.245.4.F485. PMID 6194692.
  12. ^ "Diabetic nephropathy (kidney disease) - Symptoms and causes". Mayo Clinic. Retrieved 2022-08-16.
  13. ^ Whiteside, Catharine I.; Dlugosz, John A. (2002-06-01). "Mesangial cell protein kinase C isozyme activation in the diabetic milieu". American Journal of Physiology. Renal Physiology. 282 (6): F975–F980. doi:10.1152/ajprenal.00014.2002. ISSN 1931-857X. PMID 11997313.
  14. ^ Kapor-Drezgic, J.; Zhou, X.; Babazono, T.; Dlugosz, J. A.; Hohman, T.; Whiteside, C. (June 1999). "Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent". Journal of the American Society of Nephrology. 10 (6): 1193–1203. doi:10.1681/ASN.V1061193. ISSN 1046-6673. PMID 10361857.
  15. ^ Xia, Ling; Wang, Hong; Munk, Snezana; Frecker, Helena; Goldberg, Howard J.; Fantus, I. George; Whiteside, Catharine I. (2007-11-01). "Reactive oxygen species, PKC-β1, and PKC-ζ mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells". American Journal of Physiology. Endocrinology and Metabolism. 293 (5): E1280–E1288. doi:10.1152/ajpendo.00223.2007. ISSN 0193-1849. PMID 17711990. S2CID 41867030.
  16. ^ Kwan, Janice; Wang, Hong; Munk, Snezana; Xia, Ling; Goldberg, Howard J.; Whiteside, Catharine I. (2005-12-01). "In high glucose protein kinase C-ζ activation is required for mesangial cell generation of reactive oxygen species". Kidney International. 68 (6): 2526–2541. doi:10.1111/j.1523-1755.2005.00660.x. ISSN 0085-2538. PMID 16316329.
  17. ^ Whiteside, Catharine; Wang, Hong; Xia, Ling; Munk, Snezana; Goldberg, Howard J.; Fantus, I. George (2009). "Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells". Experimental Diabetes Research. 2009: 1–11. doi:10.1155/2009/910783. PMC 2709725. PMID 19609456.
  18. ^ Lieff, Susan; Banack, Jeannine Girard-Pearlman; Baker, Lindsay; Martimianakis, Maria Athina; Verma, Sarita; Whiteside, Catharine; Reeves, Scott (July 2013). "Understanding the Needs of Department Chairs in Academic Medicine". Academic Medicine. 88 (7): 960–966. doi:10.1097/ACM.0b013e318294ff36. ISSN 1040-2446. PMID 23702526. S2CID 9257629.
  19. ^ Whiteside, Catharine; Verma, Sarita (2015), "Universal Lessons for Academic Health Science Centers—Recognizing the Value of Integration", The Transformation of Academic Health Centers, Elsevier, pp. 39–46, doi:10.1016/b978-0-12-800762-4.00005-0, ISBN 978-0-12-800762-4, retrieved 2022-08-17
  20. ^ a b c "Catharine Whiteside, CM, MD, PhD, FRCP(C), FCAHS – Research Canada". Retrieved 2022-08-17.
  21. ^ Office of the Secretary to the Governor General. "Dr. Catharine Whiteside". The Governor General of Canada. Retrieved October 4, 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Catharine_Whiteside&oldid=1250612340"